Legal Guide
A provider's guide to the legal status of compounded semaglutide — FDA shortage rules, 503A regulations, and what you need to know to prescribe legally.
Yes — compounded semaglutide is legal when prescribed by a licensed provider and compounded by a licensed pharmacy under specific regulatory conditions. Here's what providers need to know.
Under the Federal Food, Drug, and Cosmetic Act, compounding of commercially available drugs is permitted when those drugs are on the FDA Drug Shortage List. Semaglutide has been on the shortage list, allowing licensed compounding pharmacies to prepare compounded versions for individual patients.
Additionally, compounding is permitted when a provider determines that a commercially available product does not meet the medical needs of a specific patient — for example, when a different dosage form, concentration, or combination is clinically needed.
The regulatory framework differs by pharmacy type:
For a detailed comparison: 503A vs 503B Compounding Pharmacy Guide
When choosing a compounding pharmacy for semaglutide, providers should verify:
Promise Pharmacy meets all of these standards as a licensed 503A compounding pharmacy.
GLP-1 compounding regulations are evolving. FDA shortage list status, state-level pharmacy rules, and federal compounding guidance can change. Promise Pharmacy monitors regulatory changes and communicates updates to provider partners proactively.